Director of Medical Research, Product Development and Introduction, FHI 360
Kavita Nanda, MD, MHS, Director of Medical Research, FHI 360, is an obstetrician/gynecologist who has devoted her career to developing and improving the use of contraceptive methods for women. She was a co-investigator and chair of the contraceptive-safety committee for the Evidence for Contraceptive Options (ECHO) trial, a multicenter randomized trial of three different contraceptives and HIV acquisition in 7,800 African women at high risk of HIV. Dr. Nanda has served as the principal investigator for several FHI 360 studies, including addressing the safety of hormonal contraceptives among women with various medical conditions, and as study medical director for several large HIV prevention trials. Currently, Dr. Nanda is the director of a program to develop a new biodegradable implant for contraception funded by the Bill and Melinda Gates Foundation.
Findings from the ECHO trial led to an increased focus in HIV prevention in family planning programs. Here's what else needs to happen in the COVID-19 context.
chat_bubble0 Commentvisibility52640 Views
Listen to “Inside the FP Story”
Grab a cup of coffee or tea and listen in on honest conversations with family planning program experts around the world as they share what has worked in their settings — and what to avoid — in our podcast series, Inside the FP Story.
Click on the image above to visit the podcast page or on your preferred provider below to listen to Inside the FP Story.